“Our primary focus at Milestone is preparing for potential FDA approval of CARDAMYST nasal spray for the management of PSVT,” said Joseph Oliveto, President and Chief Executive Officer of Milestone ...

EPS: $0.24 in Q3 vs. -$0.26 in the same period last year. Analysts projected $0.26 per share Revenue: $4.328 billion in Q3 vs. $3.310 billion in the same period last year. Sea NewsMORE Related Stocks ...

Operator Good afternoon, and welcome to Skyworks Solutions fourth-quarter fiscal year 2024 earnings call. This call is being recorded. At this time, I will turn the call over to Raji Gill, vice ...